Evidence map›Paper›PMID 30929558›Full record

ArticleCancer biology & therapy2019

EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.

Ting Lei, Xiaodong Zhu, Kai Zhu, Fuxin Jia, Siqiao Li

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Frontiers in pharmacology · 2021
    Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ting Leia Department of hepatobiliary and pancreatic surgery , Luoyang Central Hospital, affiliated with Zhengzhou University , Luoyang city , Henan Province China.
Xiaodong Zhub Department of liver surgery and Transplantation , Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai China.
Kai Zhub Department of liver surgery and Transplantation , Liver Cancer Institute, Zhongshan Hospital, Fudan University , Shanghai China.
Fuxin Jiaa Department of hepatobiliary and pancreatic surgery , Luoyang Central Hospital, affiliated with Zhengzhou University , Luoyang city , Henan Province China.
Siqiao Lia Department of hepatobiliary and pancreatic surgery , Luoyang Central Hospital, affiliated with Zhengzhou University , Luoyang city , Henan Province China.
Luoyang Central Hospital Affiliated to Zhengzhou University · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) are regarded as a group of biomarkers in the initiation and development of various cancers, including hepatocellular carcinoma (HCC). LncRNA FOXD2-AS1 has been studied in human colorectal cancer and glioma as an oncogene. However, the function and mechanism of lncRNA FOXD2-AS1 in hepatocellular carcinoma are marked. In this study, we found that high expression of FOXD2-AS1 predicted poor prognosis of HCC patients in the TCGA database. The dysregulation of FOXD2-AS1 was determined in HCC tissues and cell lines by qRT-PCR. Functionally, silenced FOXD2-AS1 efficiently suppressed HCC progression by regulating cell proliferation, apoptosis, migration and epithelial-mesenchymal transition (EMT). Mechanistically, FOXD2-AS1 was found to be activated by the transcription factor EGR1. Furthermore, FOXD2-AS1 could activate the Wnt/β-catenin signaling pathway. The mechanism contributed to the interaction between FOXD2-AS1 and Wnt/β-catenin signaling pathway was analyzed. It was uncovered that FOXD2-AS1 enhanced the activity of Wnt/β-catenin signaling pathway by epigenetically silencing the inhibitor of Wnt/β-catenin signaling pathway (DKK1). Rescue assays demonstrated that DKK1 and Wnt/β-catenin signaling pathway involved in FOXD2-AS1-mediated HCC progression. In conclusion, our study demonstrated that EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.

Indexed as

Gene Expression Regulation, NeoplasticWnt Signaling PathwayApoptosisBiomarkers, TumorCarcinoma, HepatocellularCell Line, TumorCell MovementCell ProliferationEpigenesis, GeneticEpithelial-Mesenchymal TransitionHumansIntercellular Signaling Peptides and ProteinsLiver NeoplasmsMitochondrial ProteinsPeptide Elongation Factor GPrognosisBiomarkers, TumorDKK1 protein, humanGFM1 protein, humanIntercellular Signaling Peptides and Proteinslong non-coding RNA FOXD2-AS1, humanMitochondrial ProteinsPeptide Elongation Factor GRNA, Long NoncodingEGR1FOXD2-AS1hepatocellular carcinomamigrationproliferationWnt/β-catenin signaling pathway

Identifiers

PMID30929558
PMCPMC6606006
OpenAlexW2926096131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.